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S16 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIIntroductionBacterial resistance to antibiotics has become one of the major
threats of human health (http://www.cdc.gov/drugresistance/
threat-report-2013/index/html). Extensive drug resistance
(XDR) refers to the phenomenon in some bacteria that shows
resistance to nearly all antimicrobial agents available except one
or two. XDR emerges primarily in Gram-negative bacilli
(GNB), especially Enterobacteriaceae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia. For
the infections caused by XDR bacteria, efﬁcacious treatment is
limited, and no data are available from large series of ran-
domized clinical studies at the present time. Antimicrobial
monotherapy, including the old drug polymyxin and the newer
antibiotic tigecycline, usually cannot provide satisfactory efﬁ-
cacy. Combination antimicrobial therapy is used in most cases.
XDR infection mostly develops in patients with severe under-
lying disease, immunodeﬁciency and/or repeated long-term use
of broad-spectrum antimicrobial agents and is associated with
poor clinical outcome. As a consequence, XDR has become
one of the most troublesome issues in current management of
bacterial infections. This consensus statement was formulated
after back-and-forth discussion and consultation with relevant
clinical experts, microbiologists and pharmacologists who are
working in the ﬁeld of infectious diseases in China to help
improve the clinical management of XDR bacterial infections.DeﬁnitionsAn expert consensus onMDR, XDR and pandrug-resistant (PDR)
bacteria was proposed in 2012 via a joint initiative of the European
Centre for Disease Prevention and Control (ECDC) and the US
Centers for Disease Control and Prevention (CDC), involving the
relevant experts from the United States and many European
countries [1]. This expert consensus is now widely referenced in
China and other countries to deﬁne bacterial resistance.
Multidrug resistant (MDR)
The isolate is nonsusceptible to at least three antimicrobial
categories within its susceptibility spectrum (including resistant
and intermediate). Resistance to one antimicrobial category is
deﬁned when the isolate is nonsusceptible to at least one agent
in the recommended list for susceptibility testing of the cor-
responding category.
Extensively drug resistant (XDR)
The isolate is nonsusceptible to all but two or fewer antimi-
crobial categories (mainly polymyxin and tigecycline). TheClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licedetermination of resistance to one antimicrobial category is the
same as for MDR.
Pandrug resistant (PDR)
The isolate is nonsusceptible to all agents in all the antimicrobial
categories in current clinical use.
The concepts of PDR and XDR are dynamic and changing as
a result of the available antimicrobial categories, which vary
with time and country. For example, after tigecycline was
launched for clinical use, the previous PDR strains of
A. baumannii could become XDR if susceptible to tigecycline.
Determination of antimicrobial-resistant phenotypes
Disk diffusion, agar dilution and broth microdilution suscepti-
bility testing methods as well as other commercial testing sys-
tems are used in clinical microbiology laboratories to determine
the antimicrobial-resistant phenotypes of clinical isolates so as
to identify it as a MDR, XDR or PDR strain. The minimum
inhibitory concentration (MIC) values of antimicrobial agents or
the diameter of inhibition zone in disk diffusion testing should
be determined for XDR strains if possible to provide the basis
for selection of antimicrobial agents and the dosage in combi-
nation antimicrobial therapy.
Lists of antimicrobial categories proposed for antimicrobial
susceptibility testing of various bacterial types and the corre-
sponding breakpoints for interpretation of susceptibility testing
results usually follow the guidelines of the Clinical Laboratory
Standards Institute (CLSI) [2], the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (http://www.
eucast.org/clinical_breakpoints/) and the United States Food
and Drug Administration (FDA). Cefoperazone–sulbactam is
one of the most commonly used antimicrobials for the treat-
ment of Acinetobacter spp. infections and routinely tested in
China. The breakpoints of cefoperazone–sulbactam usually
follow the recommendation of Jones et al. [3]: susceptible (S),
16/8 mg/L; intermediate (I), 32/16 mg/L; and resistant (R),
64/32 mg/L.
The recommended antimicrobial categories and agents for
testing various common XDR-GNB are presented in Table 1
(http://www.eucast.org/clinical_breakpoints/) [2].
Some of the special mechanisms underlying bacterial resis-
tance are predictive of the possibility of XDR. For example,
production of carbapenemase is the main mechanism of car-
bapenem resistance in Enterobacteriaceae. At present, carba-
penemase production is primarily detected by phenotype
testing and molecular biologic methods. Phenotype testing
methods include modiﬁed Hodge test, inhibitor-based method
and double-disk synergy test. Phenotype testing methods are
simple to operate, practical, cost-effective and convenient for
routine testing, but the results cannot be available quicklyEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
nses/by-nc-nd/4.0/)
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Additionally, such methods cannot provide the speciﬁc type of
carbapenemase and related information. PCR-based sequence
analysis of the carbapenemase gene is now the recognized
reference standard test of carbapenemase. In addition, the
commercial microarray chips or matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-TOF)
can also be used to detect carbapenemases.Mechanisms of antibiotic resistance in XDR-
GNBThe XDR phenotype of Enterobacteriaceae is primarily due to
production of carbapenemase [4–6]. Such XDR strains may
have other mechanisms of resistance to antibiotics such as
production of extended spectrum β-lactamases [5], AmpC
β-lactamase, expressing efﬂux pump [6] or porin mutation [7].
In China, the commonest type of carbapenemase produced by
Enterobacteriaceae strains is class A carbapenemase KPC (KPC-
2), and metalloenzyme IMP, VIM and NDM-1 enzymes are re-
ported sporadically.
The mechanisms of the antibiotic resistance in A. baumannii
are also very complex, usually involving multiple mechanisms
simultaneously, including production of multiple β-lactamases,
reduced membrane permeability and increased expression of
efﬂux pump [8]. Its XDR phenotype is primarily attributed to
expressing various carbapenemases. Studies on the clinical
strains isolated in our country have found that the carbapene-
mases produced by A. baumannii mainly include OXA-type
enzymes (predominately OXA-23-like), metalloenzymes (IMP,
VIM and NDM) and Ambler class A β-lactamases (KPC and
GES) [9], as well as increased expression of efﬂux pump
(AdeABC).
The XDR of P. aeruginosa usually results from the joint effects
of multiple mechanisms of resistance [10,11], including pro-
duction of multiple β-lactamases (especially carbapenemases),
high-level expression of efﬂux pumps, target modiﬁcation and
alteration of outer membrane proteins. The formation of bioﬁlm
also has an important effect on the in vivo susceptibility to
antimicrobial agents. In China, resistance of P. aeruginosa strains
to carbapenems is primarily due to the loss of porin (OprD2)
and high expression of efﬂux pump (Mex-Opr), as well as pro-
duction of metalloenzymes (e.g. IMP, VIM and NDM).
S. maltophilia strains show intrinsic resistance to multiple
antimicrobial categories including carbapenems. These strains
also have multiple other mechanisms of acquired resistance
mediated by chromosomes, plasmids, transposons or integrons,
including production of multiple β-lactamases, multidrug efﬂuxClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access artipumps, class I integron and Insertion sequence common region
(ISCR) elements associated with resistance to trimethoprim–
sulfamethoxazole (TMP-SMX), phosphoglucomutase (SpgM)
associated with resistance to multiple antimicrobial agents,
reduction in outer membrane permeability, SmQnr de-
terminants associated with resistance to quinolones and mu-
tations of bacterial gyrase genes [12,13].Epidemiology of XDR-GNBThe data of CHINET, a bacterial resistance surveillance
network in China, showed that XDR-GNB strains in China are
mainly found in A. baumannii, Klebsiella pneumoniae and P. aer-
uginosa. During 2008 to 2014, the prevalence of XDR strains in
A. baumannii and K. pneumoniae increased from 10.9% to 19.7%
and from 0.3% to 3.2%, respectively, whereas XDR
P. aeruginosa decreased slightly from 2.1% to 1.6% [14]. During
2005–2014, the imipenem resistance rates in K. pneumoniae
increased from 2.4% to 10.5%, while in Escherichia coli, the
resistance rates were stable (approximately 1%). The imipenem
resistance rates in A. baumannii increased from 31% to 62.4%,
whereas the imipenem resistance rate in P. aeruginosa
decreased from 31% to 26.6% during this time [15]. The
prevalence and phenotypic characteristics of carbapenem-
resistant E. coli and K. pneumoniae and of XDR P. aeruginosa
and A. baumannii isolated from blood cultures in China are
addressed elsewhere in this issue [16].Risk factors and clinical characteristics of
XDR-GNB infectionsThe single most important risk factor for extensive resistance in
GNB is long-term exposure to antimicrobial agents, especially
extended-spectrum antimicrobial agents [17]. Cephalosporins
and other antimicrobial agents are used to supplement animal
feed stuff in some regions, which increases the resistance of the
colonizing bacteria in animals, especially Enterobacteriaceae,
which may facilitate the spread of resistant bacteria [18]. The
other risk factors leading to emergence of resistance are
explained below, with speciﬁc microorganisms.
XDR Enterobacteriaceae infection
The most common species of XDR Enterobacteriaceae is K.
pneumoniae, followed by E. coli. These strains usually cause in-
fections of lungs, urinary tract and bloodstream, as well as skin
and soft tissue. The risk factors for XDR Enterobacteriaceae
infections include critical underlying diseases, previous use off of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 1. Antimicrobial categories and agents for testing extensively drug-resistant Gram-negative bacilli
Antimicrobial category Antimicrobial agent Enterobacteriaceae
Pseudomonas
aeruginosa
Acinetobacter
baumannii
Stenotrophomonas
maltophilia
Penicillins Ampicillin + − − −
β-Lactam/β-lactamase inhibitor
combinations
Amoxicillin–clavulanate + − − −
Ampicillin–sulbactam + − + −
Cefoperazone–sulbactam + + + +
Ticarcillin–clavulanate + + + +
Piperacillin–tazobactam + + + −
Third- and fourth-generation
cephalosporins
Cefotaxime or ceftriaxone + − + −
Ceftazidime + + + +
Cefepime + + + −
Monobactams Aztreonam + + − −
Cephamycins Cefoxitin + − − −
Cefmetazole + − − −
Carbapenems Ertapenem + − − −
Imipenem + + + −
Meropenem + + + −
Aminoglycosides Gentamicin + + + −
Amikacin + + + −
Fluoroquinolones Ciproﬂoxacin + + + −
Levoﬂoxacin + + + +
Sulphonamides Trimethoprim–sulphamethoxazole + − + +
Chloramphenicol Chloramphenicol + − − +
Polymyxins Polymyxin E + + + −
Polymyxin B + + + −
Tetracyclines Doxycycline + − + −
Minocycline + − + +
Glycylcyclines Tigecycline + − + +
Others Fosfomycin + + − −
+, antimicrobial suggested for susceptibility testing; −, antimicrobial not suggested for susceptibility testing.
S18 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIantimicrobial agents, stay in the intensive care unit (ICU), solid
organ or blood transplantation, surgical operation and cathe-
terization, and indwelling drainage tube. XDR Entero-
bacteriaceae strains may colonize the intestinal tract for a long
time (up to several months) and result in spread of the resistant
strain in the hospital. Some of the colonizing bacteria may ﬁnally
evolve to clinical infection [19,20].
XDR Acinetobacter infection
XDR Acinetobacter strains are mostly found in hospital-acquired
pneumonia (HAP), mainly in ICU patients under mechanical
ventilation. Recently, an epidemiologic survey on HAP con-
ducted in China showed that Acinetobacter spp. was the most
common pathogen of HAP and that 76.8% of the Acinetobacter
strains causing HAP were resistant to carbapenems [21]. Aci-
netobacter strains isolated from sputum should be differentiated
to infection or colonization. A. baumannii-related bloodstream
infection is usually the result of pulmonary or abdominal
infection, or device-related infections. Efforts should be made
to identify the primary source of infection and possible sec-
ondary sites of infection. Skin and soft tissue infections caused
by A. baumannii mainly occur in patients with diabetes mellitus
or other underlying diseases, or a history of surgery or trauma,
especially those with a history of trauma and water contact. A
study suggested that XDR A. baumannii-related infection of
central nervous system may be acquired via the respiratory
tract, especially with ventilators, in addition to invasive pro-
cedures such as surgery [22]. Risk factors for XDR A. baumanniiClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceinfection include general anesthesia, stay in ICU, prior hospi-
talization, and prior use of multiple classes of antimicrobial
agents [22].
XDR P. aeruginosa infection
Infections caused by P. aeruginosa are mostly pulmonary,
bloodstream, skin and soft tissue, abdominal and urinary tract
infections. The predisposing factors for XDR P. aeruginosa in-
fections include chronic obstructive pulmonary disease, long
hospital stay before infection, mechanical ventilation, critical
disease (Acute Physiology and Chronic Health Evaluation
(APACHE) II score >16) and inappropriate antimicrobial
monotherapy [23,24]. A study indicated that prior use of ﬂu-
oroquinolones was one of the independent risk factors for
emergence of XDR P. aeruginosa infection [24].
XDR S. maltophilia infection
In 2004, 17 PDR strains of S. maltophilia were isolated from a
hospital in Taiwan. The MIC ranges of tigecycline, TMP-SMX
and levoﬂoxacin against these strains were 4–32, 8–32 and
16–64 mg/L, respectively. Seven strains were isolated from
patients with infections (six from pneumonia and one from bile
tract infection), and the remaining ten strains were from
colonized patients. For 12 of the 17 PDR S. maltophilia strains,
non-PDR S. maltophilia strains had been isolated before the
emergence of pandrug resistance, which suggests that the
antimicrobial resistance was selected by antimicrobial therapy.
Mortality of the patients with PDR-strain infection was higherEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
nses/by-nc-nd/4.0/)
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10%) [25]. Risk factors for S. maltophilia infection included a
long stay in the ICU, mechanical ventilation lasting >7 days,
tracheotomy and use of broad-spectrum antimicrobial agents
(e.g. carbapenems, broad-spectrum cephalosporins and ﬂuo-
roquinolones). S. maltophilia strains are intrinsically resistant to
carbapenems. Furthermore, carbapenem therapy may promote
the growth of S. maltophilia strains [26]. Prior use of ﬂuo-
roquinolones, piperacillin–tazobactam and carbapenems will
increase resistance of such bacteria to ﬂuoroquinolones and
TMP-SMX. Severe underlying disease is also considered as one
of the risk factors for the emergence of XDR S. maltophilia [27].Antimicrobial therapy for XDR-GNB
infectionPrinciples of antimicrobial therapy of XDR-GNB
infection
1. When a strain of XDR-GNB is isolated from clinical speci-
mens, especially XDR A. baumannii or S. maltophilia, a distinc-
tion should be made between infection and colonization.
2. Appropriate effective antimicrobial agents should be
selected according to the results of susceptibility testing. When
the strain is nonsusceptible to all the antimicrobial agents
tested, the agents showing intermediate or inhibition zone or
MIC value closer to the breakpoints of susceptibility (or in-
termediate) for that strain may be selected for combination
therapy at a higher dosage.
3. Combination therapy is usually used to manage XDR-GNB
infections.
4. The dosing regimen should be designed according to
pharmacokinetic and pharmacodynamic proﬁles, e.g. higher
dose and/or longer duration of intravenous infusion for β-lac-
tams such as carbapenems, high maximum concentration
(Cmax) and/or area under the curve/MIC or Cmax/MIC values
for quinolones and aminoglycosides.
5. The dose of antimicrobial therapy should be adjusted
appropriately in patients with hepatic or renal impairment and
elderly patients.
6. Every effort should be made to eliminate the risk factors
of infection and control of infection source, and to actively
address the primary disease.Selection of antimicrobial agents for XDR-GNB
infections
A limited number of antimicrobial agents are now available for
XDR-GNB infections. Considering the in vitro susceptibility,
tigecycline and polymyxins are the most active for XDR-GNB;Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access artihowever, limited clinical studies indicate that high rate of clinical
failure is observed with tigecycline or polymyxin monotherapy.
Combined antimicrobial therapy (two- or three-drug combi-
nations) is usually used to manage XDR-GNB infections, largely
on the basis of case reports, case series or small cohort studies;
solid evidence is needed to justify the advantage of combination
therapy [28] (Table 2).
Common antimicrobial agents for treatment of XDR-
GNB infections
Aminoglycosides. Studies indicate that aminoglycosides alone
have achieved favourable efﬁcacy in treating carbapenem-
resistant K. pneumoniae infections, 80% of which are blood-
stream infections [19]. The antibiotics of this category are
usually combined with other antimicrobial agents to treat in-
fections caused by XDR Enterobacteriaceae, P. aeruginosa or
A. baumannii [29–31]. A dose of 15 mg/kg per day is recom-
mended for amikacin or isepamicin in many countries, but in
China the dose is lower because therapeutic drug monitoring
for aminoglycosides has not yet been implemented. For patients
with severe infection and normal renal function, 0.8 g/day once
daily is recommended. Considering the increasing use of ami-
noglycosides in the treatment of MDR and XDR bacterial in-
fections, a relatively high dose is recommended; the
establishment of aminoglycoside therapeutic drug monitoring
methods and implementation in clinical use are needed in
countries where aminoglycoside therapeutic drug monitoring
has not yet been used.
Carbapenems. Time-kill assays revealed antimicrobial synergism
for imipenem in combination with colistin (75%), tigecycline
(50%), ampicillin/sulbactam (42%) and amikacin (42%) for
carbapenem-resistant A. baumannii [32]. Several clinical studies
have suggested that carbapenems in combination with other
antimicrobial agents such as polymyxins are associated with
better efﬁcacy for carbapenem-resistant Enterobacteriaceae
(CRE) infections than carbapenem monotherapy or other
antimicrobial combinations [19,33–35]. Studies indicate that
carbapenems can be used in a high-dose (e.g. meropenem 2 g
every 8 hours), prolonged-infusion (2–3 hours) regimen to
treat infections caused by carbapenem-resistant K. pneumoniae
strains with MICs of 8 mg/L [19,34,36]. If possible, exact
carbapenem MIC value or inhibition zone are welcome to be
reported for XDR- or PDR-GNB for determining whether
carbapenems can be used in combination therapy. Meropenem
and imipenem are the commonly used carbapenems, but not
ertapenem because it is not active against A. baumannii and P.
aeruginosa, with a low recommended dose of 1 g once a day.
They are usually used in combination with polymyxins, tigecy-
cline, fosfomycin or rifampicin [32,37].f of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 2. Combination antimicrobial therapies described for extensively drug-resistant (XDR) Gram-negative bacilli infections
Infection Two-drug combination Three-drug combination
XDR Enterobacteriaceae
[19,33,40,59,60]
Tigecycline-based combinations:
 Tigecycline + aminoglycosidesa
 Tigecycline + carbapenemsb
 Tigecycline + fosfomycin
 Tigecycline + polymyxin
Polymyxin-based combinations:
 Polymyxin + carbapenems
 Polymyxin + tigecycline
 Polymyxin + fosfomycin
Other combinations:
 Fosfomycin + aminoglycosidesa
 (ceftazidime or cefepime) + amoxicillin–clavulanic acid
 Aztreonam + aminoglycosidesa
 Tigecycline + polymyxin + carbapenemsb
XDR Acinetobacter baumannii
[42,49,54,55,64]
Combinations based on sulbactam or its ﬁxed-dose combination:
 (cefoperazone–sulbactam or ampicillin–sulbactam) + tigecycline
 (cefoperazone–sulbactam or ampicillin–sulbactam) + doxycycline
 Sulbactam + carbapenemsb
 Tigecycline-based combinations:
 Tigecycline + (cefoperazone–sulbactam or ampicillin–sulbactam)
 Tigecycline + carbapenemsb
 Tigecycline + polymyxin
Polymyxin-based combinations:
 Polymyxin + carbapenemsb
 Polymyxin + tigecycline
 Cefoperazone–sulbactam + tigecycline + carbapenemsb
 Cefoperazone–sulbactam + doxycycline + carbapenemsb
 Imipenem + rifampicin + (polymyxin or tobramycin)
XDR Pseudomonas aeruginosac
[29,30,40,43]
Polymyxin-based combinations:
 Polymyxin + antipseudomonal β-lactamsd
 Polymyxin + ciproﬂoxacin
 Polymyxin + fosfomycin
 Polymyxin + rifampicin
Antipseudomonal β-lactams-based combinations:
 Antipseudomonal β-lactamsd + aminoglycosidesa
 Antipseudomonal β-lactamsd + ciproﬂoxacin
 Antipseudomonal β-lactamsd + fosfomycin
Ciproﬂoxacin-based combinations:
 Ciproﬂoxacin + antipseudomonal β-lactamsd
 Ciproﬂoxacin + aminoglycosidesa
Combination of two β-lactams:
 (ceftazidime or aztreonam) + piperacillin–tazobactam
 Ceftazidime + cefoperazone–sulbactam
 Aztreonam + ceftazidime
 Polymyxin + antipseudomonal β-lactamsd + ciproﬂoxacin
 Polymyxin + antipseudomonal β-lactamsd + fosfomycin
 Polymyxin IV infusion + carbapenems + polymyxin
aerosol inhalation
 Aztreonam + ceftazidime + amikacin
XDR Stenotrophomonas maltophiliae
[45,46,51]
Trimethoprim–sulphamethoxazole-based combinations:
 Trimethoprim–sulphamethoxazole + (ticarcillin–clavulanic acid
or cefoperazone–sulbactam)
 Trimethoprim–sulphamethoxazole + ﬂuoroquinolonesf
 Trimethoprim–sulphamethoxazole + minocycline
 Trimethoprim–sulphamethoxazole + ceftazidime
 Trimethoprim–sulphamethoxazole + polymyxin
Quinolones-based combinations:
 Fluoroquinolonesf + trimethoprim–sulphamethoxazole
 Fluoroquinolonesf + (ticarcillin–clavulanic acid or
cefoperazone–sulbactam)
 Fluoroquinolonesf + ceftazidime
Polymyxin-based combinations:
 Polymyxin + ticarcillin–clavulanic acid
 Polymyxin + trimethoprim–sulphamethoxazole
aAminoglycosides include amikacin, isepamicin, etc.
bCarbapenems include meropenem, imipenem, etc. (not ertapenem).
cMost data are from in vitro studies or case reports of multidrug resistant or XDR P. aeruginosa. Data from clinical studies are limited for combination therapies.
dAntipseudomonal β-lactams refer to the β-lactams active against P. aeruginosa, such as carbapenems (meropenem, imipenem), ceftazidime, aztreonam, piperacillin–tazobactam and
cefoperazone–sulbactam.
eMost data are from in vitro studies or case reports of multidrug-resistant S. maltophilia. The data from clinical studies are limited for combination therapies.
fFluoroquinolones include ciproﬂoxacin, levoﬂoxacin and moxiﬂoxacin.
S20 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIFosfomycin. The majority (95%) of the carbapenemase-
producing Enterobacteriaceae strains are susceptible to fosfo-
mycin. Most (83%) of the metalloenzyme-producing strains are
also susceptible to fosfomycin [38]. In China, approximately
40% of the CRE isolates were sensitive to fosfomycin [39].
Intravenous fosfomycin can be used in combination with poly-
myxin, tigecycline, carbapenems and aminoglycosides to treat
carbapenemase-producing XDR or PDR K. pneumoniae andClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceP. aeruginosa infections, with a clinical success rate of 54.2% and
bacterial eradication rate of 56.3% in 48 ICU patients. The main
adverse event was reversible hypokalaemia [40]. Fosfomycin
resistance can develop during therapy, supporting the idea of
using this agent in combination [40,41]. The dosing regimen of
fosfomycin is 8 g every 8 hours or 6 g every 6 hours by
intravenous infusion. Clinical studies are currently limited in
this respect. Both oral and intravenous fosfomycin are availableEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
nses/by-nc-nd/4.0/)
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treatment of methicillin-resistant Staphylococcus aureus and
Enterococcus infections in combination with vancomycin. Use of
fosfomycin is increasing in XDR-GNB infections.
Polymyxins. This category of antibiotic includes polymyxin B and
polymyxin E (colistin). Polymyxins have good in vitro activity
against various highly resistant Gram-negative clinical isolates.
Synergistic antimicrobial effect is observed when it is combined
with carbapenems, quinolones, piperacillin–tazobactam, tige-
cycline or doxycycline [29,30,42–44]. Approximately 68% to
79% of S. maltophilia isolates are susceptible to polymyxins
[44,45]. However, only 37.5% of MDR strains are susceptible
[46]. Polymyxin is mainly used to treat various XDR-GNB in-
fections. There is apparent heterogeneous resistance to poly-
myxins in these Gram-negative strains [47]. The mutation
prevention concentration of polymyxins is high for A. baumannii
[48]. Polymyxins are usually used in combination with carba-
penems, tigecycline or fosfomycin [47]. For the elderly and the
patients with reduced renal function, special attention should
be taken to monitor renal function.
The recommended dosages of polymyxin E (colistimethate
sodium, CMS) are 2.5–5.0 mg/kg per day of colistin-base ac-
tivity (CBA) provided by intravenous infusion in two to four
divided doses [49]. One million international units of CMS is
approximately equivalent to 30 mg CBA and 80 mg CMS.
Because the two possible ways of expressing a colistin dose in
milligrams (ie, as milligrams of CBA or as milligrams of CMS)
can lead to medication errors that threaten patient safety, the
Prato polymyxin consensus suggests that the expression of
dose as milligrams of CMS in the dose section of product in-
formation should cease [50]. The daily dose of CMS should not
exceed 9 million units (Europe) or 300 mg (5 mg/kg) of CBA
(United States). Colistimethate 30–60 mg of CBA can be used
by aerosol inhalation two times a day to treat pulmonary in-
fections caused by XDR bacteria. A supply of at least one of
polymyxins (colistin or polymyxin B) should be maintained as
last-line antibiotics for the treatment of XDR bacterial in-
fections in countries where the products are not currently
registered, such as China.
Quinolones. Quinolone antibiotics have good antimicrobial ac-
tivity against P. aeruginosa and S. maltophilia. Newer quinolone
antibacterials such as moxiﬂoxacin are more active against
S. maltophilia than ciproﬂoxacin and levoﬂoxacin [45,51]. In
2014, 12.9% and 8.25% of the P. aeruginosa and S. maltophilia
isolates were resistant to ciproﬂoxacin, respectively [14].
Quinolones can be used in combination with β-lactams, ami-
noglycosides or polymyxins for treatment of the infections
caused by XDR P. aeruginosa [52] or S. maltophilia [45,51]. TheClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access artidaily dose of ciproﬂoxacin is generally 0.6–1.2 g for adults in
two to three divided oral doses. The recommended dose of
levoﬂoxacin for adults is usually 0.5 or 0.75 g once daily by
oral or intravenous infusion. The recommended dose of
moxiﬂoxacin for adults is 400 mg intravenous infusion once
daily.
Sulbactam and sulbactam-containing combinations. The β-lacta-
mase inhibitor sulbactam is active against Acinetobacter spp.
Thus, sulbactam-based ﬁxed-dose combinations have shown
good antimicrobial activity for Acinetobacter strains. Ampi-
cillin–sulbactam is usually used in many countries, but cefo-
perazone–sulbactam is used more frequently to treat MDR
A. baumannii infections in China, as the latter shows lower
resistance rates than the former (12% vs. 34%) [53]. In gen-
eral, the recommended upper limit of the sulbactam dose is
4.0 g/day, but it can be increased to 6.0 g/day or even 8.0 g/day
for MDR and XDR A. baumannii infections [49]. The dose
should be adjusted for patients with reduced renal function. It
can be combined with other antimicrobial agents such as
carbapenems [54] to treat infections caused by XDR A.
baumannii.
Cefoperazone–sulbactam. The usual dosing regimen is 3.0 g
(cefoperazone 2.0 g plus sulbactam 1.0 g) intravenous infusion
every 8 hours or every 6 hours. Cefoperazone–sulbactam is
usually used in combination with tigecycline, minocycline
[55,56], carbapenems or aminoglycosides to treat XDR
A. baumannii infections in China.
Tetracyclines. Minocycline is one of the few recommended anti-
microbial agents for treating S. maltophilia infections. TheUS FDA
has approved minocycline injection for treatment of A. baumannii
infections. The dosing regimen of minocycline is 100 mg intra-
venous infusion every 12 hours. Clinical data are lacking in this
respect. Currently minocycline injection is not available in China.
Minocycline tablets or doxycycline injection (an equivalent dose
of minocycline) can be used in combination with other antimi-
crobial agents for the treatment of infections caused by XDR
A. baumannii [42,55,56] or S. maltophilia [45,46,51].
Tigecycline. As the ﬁrst antibiotic of glycylcyclines, it remains
active for CRE and XDR A. baumannii. Tigecycline susceptibility
rates are 98% and 90% for carbapenem-resistant Klebsiella spp.
and Acinetobacter spp., respectively; 92% of the S. maltophilia
isolates are susceptible to tigecycline [57]. Recent reports on the
susceptibility of A. baumannii to tigecycline vary greatly [58].
Therefore, it should be used according to the results of sus-
ceptibility testing. Tigecycline is inactive against P. aeruginosa.
Tigecycline is distributed extensively in body tissues and is
associated with low blood concentration [19]. It is thereforef of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
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infection. Since its launch in China in 2012, tigecycline has been
used primarily to treat the respiratory tract, skin and soft tissue,
and abdominal infections caused by XDR A. baumannii or
Enterobacteriaceae. It is usually used in combination with cefo-
perazone–sulbactam, carbapenems or aminoglycosides. Tigecy-
cline is also used in combination with polymyxin [59]. Clinical
data are still lacking for tigecycline in the treatment of
S. maltophilia infections [45,51]. The usual dosing regimen of
tigecycline is 100 mg, followed by 50 mg every 12 hours by
intravenous infusion. Preliminary studies indicate that increasing
the tigecycline dose may improve its efﬁcacy in treating severe
bacterial infections, especially complicated intra-abdominal
infection [60], hospital-acquired pneumonia (HAP) [61] and
VAP (Ventilator-associated pneumonia) [62]. However, this
ﬁnding requires conﬁrmation. The main adverse reactions of
tigecycline are gastrointestinal reactions.
Trimethoprim–sulphamethoxazole (TMP-SMX). TMP-SMX has
good antimicrobial activity against S. maltophilia, with resistance
rates lower than 10% [14,44,45]. Approximately 87% of the
MDR S. maltophilia strains are still susceptible to this drug. TMP-
SMX combined with minocycline or ceftazidime has shown
good in vitro antimicrobial activity (partially synergistic) against
MDR S. maltophilia strains [46]. TMP-SMX is the ﬁrst choice for
treating S. maltophilia infections [45,51]. TMP-SMX is also active
against a few XDR A. baumannii and CRE strains.
Others. Rifampicin has shown certain antimicrobial activity
against A. baumannii. It can be used in combination with car-
bapenems for treatment of the infections caused by XDR
A. baumannii [63]. However, a recent randomized clinical trial
indicated that 30-day mortality is not reduced by addition of
rifampicin to colistin in serious XDR A. baumannii infections
[64]. A few XDR-GNB strains including NDM-1-producing
Enterobacteriaceae strains are susceptible to aztreonam [65],
which might be used in combination therapy for such strains.
New antimicrobial agents. Two β-lactamase inhibitor combina-
tions, ceftazidime–avibactam and ceftolozane–tazobactam,
have been approved by the US FDA for the treatment of
complicated intra-abdominal infections and complicated urinary
tract infections in the United States in February 2015 and
December 2014, respectively. Avibactam is a synthetic non-
β-lactam β-lactamase inhibitor that inhibits the activities of
Ambler class A (including extended-spectrum β-lactamase),
class C (especially AmpC) and class D (such as OXA-48)
β-lactamases as well as KPC carbapenemases. The addition of
avibactam greatly improves the activity of ceftazidime versus
most species of Enterobacteriaceae and P. aeruginosa as well.
Limited data suggest that the addition of avibactam does notClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
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[66]. A randomized active-controlled, double-blind, phase 2
trial proved that ceftazidime–avibactam plus metronidazole
was as effective and well tolerated in patients with complicated
intra-abdominal infections as meropenem [67].
Ceftolozane is a novel cephalosporin with a structure
similar to ceftazidime that is distinguished from other cepha-
losporins by improved activity against P. aeruginosa, including
various drug-resistant phenotypes such as carbapenem-,
piperacillin–tazobactam- and ceftazidime-resistant isolates, as
well as strains that are MDR isolates [68]. Phase 2 and phase 3
clinical trials of ceftolozane–tazobactam have been completed.
In a phase 2 trial, ceftolozane–tazobactam plus metronidazole
resulted in similar clinical and microbiologic success rates as
meropenem in the treatment of complicated intra-abdominal
infections [69].Control of XDR-GNB hospital infectionsThe increase of XDR-GNB infections results from the com-
bined effect of antibiotic selection pressure and spread of
resistant clones. Infection control measures must be appro-
priately integrated with antimicrobial stewardship to effectively
curb and prevent the spread of XDR-GNB, and to reduce in-
fections caused by resistant bacteria [19,70,71].
Hand hygiene
Hand hygiene is themost fundamental, effective and cost-effective
strategy for reducing cross-infections and avoiding the spread of
resistant bacteria through the hands of healthcare staff [71].
Contact precaution
The microbiology laboratory should notify clinicians in a timely
and reliable way when an XDR-GNB strain is identiﬁed. Clini-
cians may implement contact precaution measures such as single
room and partial separation of at least 1 m between beds for
patients infected with XDR-GNB and to reduce the practice of
sharing devices. Sphygmomanometer, stethoscope, thermom-
eter, infusion pump and other relevant devices should be pro-
vided speciﬁcally for patients with XDR-GNB infection [70].
When a patient infected with XDR-GNB is transferred to
another department or hospital, or leaves the ward for exami-
nation, handover procedures and warning tips are required [72].
Active screening
In the ICU and other wards with highly prevalent XDR-GNB
strains, patients should be screened with samples of perianal
and rectal swabs for CRE, wound secretion and nasopharyngeal
region for XDR nonfermenters to promptly identify resistantEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
nses/by-nc-nd/4.0/)
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[71]. The patients should be isolated appropriately. Molecular
epidemiologic measures may be adopted to track the route of
transmission if necessary to provide a rationale for blocking
transmission of resistant bacteria [73].
Environmental surface disinfection
The surface of the objects frequently contacted by healthcare
staff and patients in the hospital environment should be dis-
infected regularly and completely [71,74]. Fluorescence labeling
or the ATP Hygiene Monitoring System can be used to monitor
the effectiveness of disinfection and thus ensure that the
transmission of resistant strains is effectively blocked.
Decolonization
Patients colonized with XDR-GNB may have a whole-body
sponge bath with chlorhexidine, which is helpful for reducing
catheter-related bloodstream infections [75].Management of antimicrobial agent use in
the clinical settingWe recommend strictly adhering to indications for the clinical
use of antimicrobial agents; limiting antimicrobial use through
restriction of speciﬁc agents (e.g. carbapenems, tigecycline and
polymyxin); and formulating evidence-based treatment guide-
lines or dosing regimens according to the local proﬁle of resistant
bacteria to guide and standardize the use of antimicrobial agents.
A rational and appropriate formulary should be developed to
ensure the supply of antimicrobial agents necessary for clinical
treatment, including newer antimicrobial agents. Available evi-
dence for the effects of antimicrobial rotation or cycling on
curbing increasing antimicrobial resistance is contradictory [76].
Furthermore, in hospitals or speciﬁc wards with highly prevalent
XDR-GNB, some GNB species are highly resistant to nearly all
antimicrobial agents available. Therefore, caution must be
exercised when considering exclusion of a speciﬁc category of
antimicrobial agents in a medical institution or in speciﬁc wards.Transparency declarationAll authors report no conﬂicts of interest relevant to this article.References[1] Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME,
Giske CG, et al. Multidrug-resistant, extensively drug-resistant andClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access artipandrug-resistant bacteria: an international expert proposal for interim
standard deﬁnitions for acquired resistance. Clin Microbiol Infect
2012;18:268–81.
[2] Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing; nineteenth informational supple-
ment. CLSI document M100–S23. Wayne, PA: Clinical and Laboratory
Standards Institute; 2013.
[3] Jones RN, Barry AL, Packer RR, Gregory WW, Thornsberry C. In vitro
antimicrobial spectrum, occurrence of synergy, and recommendations
for dilution susceptibility testing concentrations of the cefoper-
azone–sulbactam combination. J Clin Microbiol 1987;25:1725–9.
[4] Santino I, Bono S, Nuccitelli A, Martinelli D, Petrucci C, Alari A.
Microbiological and molecular characterization of extreme drug-
resistant carbapenemase-producing Klebsiella pneumoniae isolates. Int
J Immunopathol Pharmacol 2013;26:785–90.
[5] Toth A, Damjanova I, Puskas E, Jánvári L, Farkas M, Dobák A, et al.
Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae
ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 2010;29:765–9.
[6] Naparstek L, Carmeli Y, Chmelnitsky I, Banin E, Navon-Venezia S.
Reduced susceptibility to chlorhexidine among extremely-drug-
resistant strains of Klebsiella pneumoniae. J Hosp Infect 2012;81:15–9.
[7] Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, et al.
Epidemiology and molecular characterization of bacteremia due to
carbapenem-resistant Klebsiella pneumoniae in transplant recipients.
Am J Transplant 2013;13:2619–33.
[8] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence
of a successful pathogen. Clin Microbiol Rev 2008;21:538–82.
[9] Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of
multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Anti-
microb Agents 2013;41:11–9.
[10] Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant
Pseudomonas aeruginosa and Acinetobacter baumannii: resistance
mechanisms and implications for therapy. Expert Rev Anti Infect Ther
2010;8:71–93.
[11] Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL. The
intrinsic resistome of Pseudomonas aeruginosa to beta-lactams. Viru-
lence 2011;2:144–6.
[12] Sanchez MB, Hernandez A, Martinez JL. Stenotrophomonas maltophilia
drug resistance. Future Microbiol 2009;4:655–60.
[13] Brooke JS. Stenotrophomonas maltophilia: an emerging global oppor-
tunistic pathogen. Clin Microbiol Rev 2012;25:2–41.
[14] Hu FP, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, et al. CHINET
2014 surveillance of bacterial resistance in China. Chin J Infect Che-
mother 2015;15:401–10.
[15] Hu FP, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, et al. Resistance
trends among clinical isolates in China reported from CHINET sur-
veillance of bacterial resistance, 2005–2014. Clin Microbiol Infect
2016;22(Suppl. 1):S9–14.
[16] Xu A, Zheng B, Xu YC, Huang ZG, Zhong NS, Zhuo C. National
epidemiology of carbapenem-resistant and extensively drug-resistant
Gram-negative bacteria isolated from blood samples in China in
2013. Clin Microbiol Infect 2016;22(Suppl. 1):S1–8.
[17] Souli M, Galanti I, Giamarellou H. Emergence of extensively drug-
resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro
Surveill 2008;13(47). pii: 19045.
[18] Liebana E, Carattoli A, Cogue TM, Hasman H, Magiorakos AP,
Mevius D, et al. Public health risks of enterobacterial isolates pro-
ducing extended-spectrum β-lactamases or AmpC β-lactamases in
food and food-producing animals: an EU perspective of epidemiology,
analytical methods, risk factors, and control options. Clin Infect Dis
2013;56:1030–7.
[19] Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT,
Daikos GL. Carbapenemases in Klebsiella pneumoniae and other
Enterobacteriaceae: an evolving crisis of global dimensions. Clin
Microbiol Rev 2012;25:682–707.f of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
S24 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMI[20] Tumbarello M, Trecarichi EM, Tumietto F, Del Bono V, De Rosa FG,
Bassetti M, et al. Predictive models for identiﬁcation of hospitalized
patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob
Agents Chemother 2014;58:3514–20.
[21] Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, et al. Adult
hospital acquired pneumonia: a multicenter study on microbiology and
clinical characteristics of patients from 9 Chinese cities. Zhonghua Jie
He He Hu Xi Za Zhi 2012;35:739–46.
[22] Li Y, Guo Q, Wang P, Zhu D, Ye X, Wu S, et al. Clonal dissemination
of extensively drug-resistant Acinetobacter baumannii producing an
OXA-23 β-lactamase at a teaching hospital in Shanghai, China.
J Microbiol Immunol Infect 2015;48:101–8.
[23] Wei SQ, Zhao ZW, Zhong WN, Zhao ZX, Ye HF, Chen HL, et al.
A case–control study on the risk factors of pandrug-resistant Pseu-
domonas aeruginosa pneumonia. Zhonghua Yi Yuan Gan Ran Xue Za
Zhi 2009;19:673–6.
[24] Pena C, Gomez-Zorrilla S, Suarez C, Dominguez MA, Tubau F,
Arch O, et al. Extensively drug-resistant Pseudomonas aeruginosa: risk
of bloodstream infection in hospitalized patients. Eur J Clin Microbiol
Infect Dis 2012;31:2791–7.
[25] Tan CK, Liaw SJ, Yu CJ, Teng LJ, Hsueh PR. Extensively drug-resistant
Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan:
microbiologic characteristics, clinical features, and outcomes. Diagn
Microbiol Infect Dis 2008;60:205–10.
[26] Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum
of a serious bacterial pathogen in patients with cancer. Clin Infect Dis
2007;45:1602–9.
[27] Pien CJ, Kuo HY, Chang SW, Chen PR, Yeh HW, Liu CC, et al. Risk
factors for levoﬂoxacin resistance in Stenotrophomonas maltophilia from
respiratory tract in a regional hospital. J Microbiol Immunol Infect
2013. pii:S1684–S1182.
[28] Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E,
Theuretzbacher U, et al. Combination therapy for carbapenem-resistant
Gram-negative bacteria. J Antimicrob Chemother 2014;69:2305–9.
[29] Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections
due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and
treatment options. Pharmacotherapy 2005;25:1353–64.
[30] Lim TP, Lee W, Tan TY, Sasikala S, Teo J, Hsu LY, et al. Effective
antibiotics in combination against extreme drug-resistant Pseudomonas
aeruginosa with decreased susceptibility to polymyxin B. PLoS One
2011;6:e28177.
[31] Yang JJ, Sun TY, Hu YJ. Multiple combination bactericidal testing against
pandrug resistant Pseudomonas aeruginosa. Chin J Infect Chemother
2010;10:357–62.
[32] Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, et al.
Comparative in vitro antimicrobial susceptibilities and synergistic
activities of antimicrobial combinations against carbapenem-
resistant Acinetobacter species: Acinetobacter baumannii versus Aci-
netobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis
2011;70:380–6.
[33] Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M,
Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumo-
niae bloodstream infections: lowering mortality by antibiotic combi-
nation schemes and the role of carbapenems. Antimicrob Agents
Chemother 2014;58:2322–8.
[34] Tumbarello M, Trecarichi1 EM, De Rosa FG, Giannella M,
Giacobbe DR, Bassetti M, et al. Infections caused by KPC-
producing Klebsiella pneumoniae: differences in therapy and mor-
tality in a multicentre study. J Antimicrob Chemother 2015;70:
2133–43.
[35] Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F,
Marchese A, et al. Predictors of mortality in bloodstream infections
caused by Klebsiella pneumoniae carbapenemase–producing K. pneu-
moniae: importance of combination therapy. Clin Infect Dis 2012;55:
943–50.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/lice[36] Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella
pneumoniae: (when) might we still consider treating with carbapenems?
Clin Microbiol Infect 2011;17:1135–41.
[37] Sun Y, Wang L, Li J, Zhao C, Zhao J, Liu M, et al. Synergistic efﬁcacy of
meropenem and rifampicin in a murine model of sepsis caused by
multidrug-resistant Acinetobacter baumannii. Eur J Pharmacol 2014;729:
116–22.
[38] Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC,
Mavromanolakis E, Samonis G. Antimicrobial susceptibility of
multidrug-resistant (MDR) and extensively drug-resistant (XDR)
Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents
2010;35:240–3.
[39] Jiang Y, Shen P, Wei Z, Liu L, He F, Shi K, et al. Dissemination of a
clone carrying a fosA3-harbouring plasmid mediates high fosfomycin
resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J
Antimicrob Agents 2015;45:66–70.
[40] Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M,
Katsiari M, et al. Outcomes of critically ill intensive care unit patients
treated with fosfomycin for infections due to pandrug-resistant and
extensively drug-resistant carbapenemase-producing Gram-negative
bacteria. Int J Antimicrob Agents 2014;43:52–9.
[41] Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin:
use beyond urinary tract and gastrointestinal infections. Clin Infect Dis
2008;46:1069–77.
[42] Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. Activities of
colistin–andminocycline–based combinations against extensive drug
resistant Acinetobacterbaumannii isolates from intensive care unit pa-
tients. BMC Infect Dis 2011;11:109.
[43] Liu LF, Li D, Chu YZ, Chen BY. In vitro activities of polymyxin B in
combination with other antimicrobials against pan-drug-resistant
strains of Pseudomonas aeruginosa. Chin J Antibiot 2012;37:524–7.
[44] Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly iso-
lated non-enteric Gram-negative bacilli. Int J Antimicrob Agents
2005;25:95–109.
[45] Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Steno-
trophomonas maltophilia: emerging disease patterns and challenges for
treatment. Expert Rev Anti Infect Ther 2011;9:471–88.
[46] Milne KE, Gould IM. Combination antimicrobial susceptibility testing of
multidrug-resistant Stenotrophomonas maltophilia from cystic ﬁbrosis
patients. Antimicrob Agents Chemother 2012;56:4071–7.
[47] Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acine-
tobacter baumannii: clinical reports, mechanisms and antimicrobial
strategies. J Antimicrob Chemother 2012;67:1607–15.
[48] Cai Y, Li R, Liang B, Bai N, Liu Y, Wang R. In vitro antimicrobial activity
and mutant prevention concentration of colistin against Acinetobacter
baumannii. Antimicrob Agents Chemother 2010;54:3998–9.
[49] Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect
Dis 2010;51:79–84.
[50] Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al.
Framework for optimisation of the clinical use of colistin and poly-
myxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015;15:
225–34.
[51] Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia:
an emerging opportunist human pathogen. Lancet Infect Dis 2009;9:
312–23.
[52] Wen YK, Cao M, Zou L, Luo YP, Sun BJ. In vitro combination anti-
microbial susceptibility testing on carbapenem-resistant Pseudomonas
aeruginosa. Chin J Antibiot 2012;37:536–8.
[53] Zhu DM, Zhang YY, Wang F. Surveillance of bacterial resistance in
Shanghai hospitals during 2006. Chin J Infect Chemother 2007;7:
393–9.
[54] Ji J, Du X, Chen Y, Fu Y, Wang H, Yu Y. In vitro activity of sulbactam in
combination with imipenem, meropenem, panipenem or cefoperazone
against clinical isolates of Acinetobacter baumannii. Int J Antimicrob
Agents 2013;41:400–1.European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
nses/by-nc-nd/4.0/)
CMI Chinese XDR Consensus Working Group XDR Gram-negative bacilli S25[55] Pei G, Mao Y, Sun Y. In vitro activity of minocycline alone and in
combination with cefoperazone–sulbactam against carbapenem-
resistant Acinetobacter baumannii. Microb Drug Resist 2012;18:
574–7.
[56] Shi Y, Xu YC, Liu Y, Du W, Rui X, Wang Y. Cefoperazone–sulbactam
plus minocycline in the treatment of extensively drug resistant Acine-
tobacter infections. Zhonghua Yi Xue Za Zhi 2012;92:2847–50.
[57] Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against
antimicrobial resistant surveillance subsets of clinical bacteria collected
worldwide (2011). Diagn Microbiol Infect Dis 2013;76:217–21.
[58] Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical
resistance to tigecycline. Int J Antimicrob Agents 2013;41:110–6.
[59] Entenza JM, Moreillon P. Tigecycline in combination with other anti-
microbials: a review of in vitro, animal and case report studies. Int J
Antimicrob Agents 2009;34:1–9.
[60] Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS.
Effectiveness and safety of high-dose tigecycline-containing regimens
for the treatment of severe bacterial infections. Int J Antimicrob
Agents 2014;44:1–7.
[61] Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J,
McGovern PC. Randomized phase 2 trial to evaluate the clinical efﬁ-
cacy of two high-dosage tigecycline regimens versus imipenem–
cilastatin for treatment of hospital-acquired pneumonia. Antimicrob
Agents Chemother 2013;57:1756–62.
[62] De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al.
High dose tigecycline in critically ill patients with severe infections due
to multidrug-resistant bacteria. Crit Care 2014;18:R90.
[63] Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter
baumannii infections: epidemiology and management. Curr Opin Infect
Dis 2010;23:332–9.
[64] Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De
Cristoforo M, Murino P, et al. Colistin and rifampicin compared with
colistion alone for the treatment of serious infections due to exten-
sively drug-resistant Acinetobacter baumannii: a multicenter, random-
ized clinical trial. Clin Infect Dis 2013;57:349–58.
[65] Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F,
Balakrishnan R, et al. Emergence of a new antibiotic resistance
mechanism in India, Pakistan, and the UK: a molecular, biological, and
epidemiological study. Lancet Infect Dis 2010;10:597–602.
[66] Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-
Wiens PR, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lac-
tamase inhibitor combination. Drugs 2013;73:159–77.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behal
This is an open access arti[67] Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study
of the efﬁcacy and safety of ceftazidime/avibactam plus metronidazole
versus meropenem in the treatment of complicated intra-abdominal
infections in hospitalized adults: results of a randomized, double-
blind, phase II trial. J Antimicrob Chemother 2013;68:1183–92.
[68] Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F,
et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase in-
hibitor combination with activity against multidrug-resistant Gram-
negative bacilli. Drugs 2014;74:31–51.
[69] Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J,
Friedland I, et al. Multicenter, double-blind, randomized, phase II trial
to assess the safety and efﬁcacy of ceftolozane–tazobactam plus
metronidazole compared with meropenem in adult patients with
complicated intra-abdominal infections. Antimicrob Agents Chemo-
ther 2014;58:5350–7.
[70] Centers for Disease Control and Prevention (CDC). Guidance for
control of infections with carbapenem-resistant or carbapenemase-
producing Enterobacteriaceae in acute care facilities. MMWR Morb
Mortal Wkly Rep 2009;58:256–60.
[71] Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M,
Frank U, et al. ESCMID guidelines for the management of the infection
control measure to reduce transmission of multidrug-resistant Gram-
negative bacteria in hospitalized patients. Clin Microbiol Infect
2014;20(Suppl. 1):1–55.
[72] Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase-producing
organisms: an ounce of prevention really is worth a pound of cure.
Infect Control Hosp Epidemiol 2008;29:1107–9.
[73] O’Fallon E, Gautam S, D’Agata EM. Colonization with multidrug-
resistant Gram-negative bacteria: prolonged duration and frequent
cocolonization. Clin Infect Dis 2009;48:1375–81.
[74] Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M,
Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-
acquired infection. N Engl J Med 2013;368:533–42.
[75] Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of
bloodstream infections by use of daily chlorhexidine baths for patients
at a long-term acute care hospital. Infect Control Hosp Epidemiol
2009;30:1031–5.
[76] Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA,
Burke JP, et al. Infectious Diseases Society of America and the Society
for Healthcare Epidemiology of America guidelines for developing an
institutional proGram to enhance antimicrobial stewardship. Clin
Infect Dis 2007;44:159–77.f of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S15–S25
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
